These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34975523)

  • 1. Treatment With Lisinopril Prevents the Early Progression of Glomerular Injury in Obese Dahl Salt-Sensitive Rats Independent of Lowering Arterial Pressure.
    Brown AK; Nichols A; Coley CA; Ekperikpe US; McPherson KC; Shields CA; Poudel B; Cornelius DC; Williams JM
    Front Physiol; 2021; 12():765305. PubMed ID: 34975523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing MIP3
    Ekperikpe US; Poudel B; Shields CA; Mandal S; Cornelius DC; Williams JM
    J Pharmacol Exp Ther; 2023 Mar; 384(3):445-454. PubMed ID: 36507846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of macrophages slows the early progression of renal injury in obese Dahl salt-sensitive leptin receptor mutant rats.
    Poudel B; Shields CA; Brown AK; Ekperikpe U; Johnson T; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2020 Jun; 318(6):F1489-F1499. PubMed ID: 32390513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats.
    Shields CA; Poudel B; McPherson KC; Brown AK; Ekperikpe US; Browning E; Sutton L; Cornelius DC; Williams JM
    Front Physiol; 2020; 11():566403. PubMed ID: 33071820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic treatment with IL-25 increases renal M2 macrophages and reduces renal injury in obese Dahl salt-sensitive rats during the prepubescent stage.
    Poudel B; Ekperikpe US; Mandal S; Wilson GE; Shields CA; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2023 Jul; 325(1):F87-F98. PubMed ID: 37167270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin reduces insulin resistance and attenuates progressive renal injury in prepubertal obese Dahl salt-sensitive rats.
    Ekperikpe US; Mandal S; Holt SJ; Daniels JK; Johnson TD; Cooper JS; Safir SM; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2023 Sep; 325(3):F363-F376. PubMed ID: 37498548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered renal hemodynamics is associated with glomerular lipid accumulation in obese Dahl salt-sensitive leptin receptor mutant rats.
    McPherson KC; Shields CA; Poudel B; Johnson AC; Taylor L; Stubbs C; Nichols A; Cornelius DC; Garrett MR; Williams JM
    Am J Physiol Renal Physiol; 2020 Apr; 318(4):F911-F921. PubMed ID: 32068459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abatacept Decreases Renal T-cell Infiltration and Renal Inflammation and Ameliorates Progressive Renal Injury in Obese Dahl Salt-sensitive Rats Before Puberty.
    Ekperikpe US; Mandal S; Bhopatkar AA; Shields CA; Coley CA; Chambers CL; Johnson TD; Cornelius DC; Williams JM
    J Cardiovasc Pharmacol; 2024 Jun; 83(6):635-645. PubMed ID: 38547515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early development of podocyte injury independently of hyperglycemia and elevations in arterial pressure in nondiabetic obese Dahl SS leptin receptor mutant rats.
    McPherson KC; Taylor L; Johnson AC; Didion SP; Geurts AM; Garrett MR; Williams JM
    Am J Physiol Renal Physiol; 2016 Oct; 311(4):F793-F804. PubMed ID: 27465994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The SS
    Poudel B; Shields CA; Ekperikpe US; Brown AK; Travis OK; Maury JC; Fitzgerald S; Smith SV; Cornelius DC; Williams JM
    Am J Physiol Regul Integr Comp Physiol; 2022 Apr; 322(4):R299-R308. PubMed ID: 35107024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats.
    Slaughter TN; Paige A; Spires D; Kojima N; Kyle PB; Garrett MR; Roman RJ; Williams JM
    Am J Physiol Regul Integr Comp Physiol; 2013 Oct; 305(7):R727-34. PubMed ID: 23926133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats.
    Kojima N; Williams JM; Slaughter TN; Kato S; Takahashi T; Miyata N; Roman RJ
    Physiol Rep; 2015 Jul; 3(7):. PubMed ID: 26169541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renoprotective effects of empagliflozin in type 1 and type 2 models of diabetic nephropathy superimposed with hypertension.
    Williams JM; Murphy SR; Wu W; Border JJ; Fan F; Roman RJ
    Geroscience; 2022 Dec; 44(6):2845-2861. PubMed ID: 35767209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of the progression of renal injury in diabetic rodent models with preexisting renal disease with chronic endothelin A receptor blockade.
    Spires D; Poudel B; Shields CA; Pennington A; Fizer B; Taylor L; McPherson KC; Cornelius DC; Williams JM
    Am J Physiol Renal Physiol; 2018 Oct; 315(4):F977-F985. PubMed ID: 29846112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium bicarbonate loading limits tubular cast formation independent of glomerular injury and proteinuria in Dahl salt-sensitive rats.
    Ray SC; Patel B; Irsik DL; Sun J; Ocasio H; Crislip GR; Jin CH; Chen J; Baban B; Polichnowski AJ; O'Connor PM
    Clin Sci (Lond); 2018 Jun; 132(11):1179-1197. PubMed ID: 29650676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats.
    Kojima N; Williams JM; Takahashi T; Miyata N; Roman RJ
    J Pharmacol Exp Ther; 2013 Jun; 345(3):464-72. PubMed ID: 23492941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
    Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
    Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mycophenolate mofetil prevents high-fat diet-induced hypertension and renal glomerular injury in Dahl SS rats.
    Spradley FT; De Miguel C; Hobbs J; Pollock DM; Pollock JS
    Physiol Rep; 2013 Nov; 1(6):e00137. PubMed ID: 24400139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis.
    Zoja C; Abbate M; Corna D; Capitanio M; Donadelli R; Bruzzi I; Oldroyd S; Benigni A; Remuzzi G
    Am J Kidney Dis; 1998 Mar; 31(3):453-63. PubMed ID: 9506682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension.
    Tian N; Thrasher KD; Gundy PD; Hughson MD; Manning RD
    Hypertension; 2005 May; 45(5):934-9. PubMed ID: 15837840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.